DRESDEN, Germany, April 29, 2021 — denovoMATRIX GmbH, a developer of technologies which enable high quality stem cell expansion, announced today that it will participate in the new European collaborative project funded by the European Union’s Horizon 2020 research and innovation program.
Project Carrier4TSC was selected as one of the top 30 proposals. The innovative project deals with the development of novel microcarriers for application in cell therapies. The Eurostar jury selection for funded projects was based on scientific relevance as well as market need for novel products and services. Carrier4TSC is a consortium of three partners, each providing unique expertise which will contribute to a novel microcarrier product for solving bottlenecks in functional mesenchymal stem cell (MSC) manufacturing.
denovoMATRIX’ coating technology and competence in stem cell biology will be complimented by the bioprocess expertise of the Technische Hochschule Mittelhessen (THM) and microcarrier production capacities of Magle Chemoswed.
“We are pleased at the recognition of the expert juries of the Eurostars program for our plans to innovate in the microcarrier field for cell therapies”, said Dr. Richard Wetzel, Managing Partner at denovoMATRIX. “Extending our good working relationship with the teams at Magle Chemoswed and the THM is something we look forward to”, added Richard.
The three-year funded project will begin in May 2021 with the goal of developing novel dissolvable microcarriers that enable the adhesion and growth of MSC in scalable bioreactors. Key metrics will be high cell harvest yields while preserving the therapeutic potential of the MSC. The consortium will take advantage of denovoMATRIX and Magle Chemoswed’s background IP-portfolios as well as the extensive bioprocess development knowledge assembled by the Technische Hochschule Mittelhessen.
About denovoMATRIX GmbH
denovoMATRIX is an extracellular matrix engineering company that enables the acceleration of cell-based therapies and development in stem cell research. The company leverages chemical synthesis, stem cell biology and design thinking to build a platform of biomaterials which address major life science challenges. By providing both cell-based therapy companies and translational researchers with solutions, denovoMATRIX is at the forefront of innovation in biomaterials.
For more information, visit: https://www.denovomatrix.com/
Contact
denovoMATRIX GmbH
Dejan Husman
Tatzberg 47/49
01307 Dresden
mail@denovomatrix.com